NEW YORK--(BUSINESS WIRE)--June 5, 2006--FermaVir Pharmaceuticals, Inc., (OTCBB:FMVR - News), committed to the development of breakthrough antiviral drugs and other therapies, announced today that the U.S. Food and Drug Administration (FDA) has responded to its pre-Investigational New Drug (IND) application for FV-100, a pro-drug of CF-1743 to address the potentially serious and debilitating viral condition known as shingles. The FDA response will enable FermaVir to proceed with clinical development of FV-100 for the treatment of shingles.
